Drug Updates
New Drugs
New Indications
Patient Teaching
News Capsules
Drug Warnings
Herbal Spotlight
Quik Tools
Drug Info
Links
Drug Info Bookstore
Feedback
Disclaimer
|
|
 temozolomide |
| Temodar |
Pharmaceutical
company:
Schering Corporation
www.temodar.com |
NEW INDICATION & DOSAGE
Newly diagnosed glioblastoma multiforme in combination with radiation therapy—
Adults: Initially, 75 mg/m2 I.V. infusion or P.O. daily for 42 days. Maintenance dose, 150 mg/m2 I.V. infusion or P.O. on days 1 to 5 of a 28-day cycle for six cycles; may increase dose to 200 mg/m2 for cycles two through six if common toxicity criteria (CTC) is grade 2 or less, absolute neutrophil count (ANC) is 1.5 × 109/L or more, and platelet count is 100 × 109/L or more. If dose was increased in cycle two, maintain dose at 200 mg/m2 for days 1 to 5 of subsequent cycles, unless toxicity occurs. If dose wasn't increased in cycle two, don't increase in subsequent cycles.
|
